Featured events

Events | Virtual

Bankruptcy and Restructuring: Navigating Distress in the Evolving Markets

22 Jun 2023

Learn more >

Events | Virtual

Private Funds Industry Live, Expanding Private Funds in Global Markets

10 Jan 2023

Watch the recording >

Events | Virtual

Private Funds Industry Live, Demystifying Private Capital Funds

6 Dec 2022

Watch the recording >
Show all events >

Case study

Supporting Portola Pharmaceuticals Inc.

11 November 2020

Portola Pharmaceuticals Inc. (“Portola”) is a San Francisco based biopharmaceutical company founded in 2003 with the mission to advance patient care in thrombosis and other hematologic disorders.

Portola elected to set up its trading company in the Netherlands due to its proximity to the European Medicines Agency (EMA) and the port of Rotterdam. In the Netherlands Portola will use a third party logistics (3PL) service provider to distribute products to wholesalers and local hospitals in various countries in Europe.

The solution
In order to trade it’s Its product Ondexxya – an antidote for medications Rivaroxaban and Apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding – it needed to set up a Dutch limited liability company (Besloten Vennootschap) in 2018 to function as the trading entity in Europe for Portola.

Our advantages
We supported Portola during the set up phase in Europe and will continued to do so when it became operational. As part of this Intertrust Group helped with the incorporation of the Dutch trading company, management services, recruitment services, product registration in the EU, payment services and legal assistance for the contracts to be concluded by the Dutch trading company. In addition, Intertrust Group and Portola have, in conjunction with Portola’s advisers, set up and implemented a governance model suitable for Portola’s European business.